


Contents lists available at bostonsciencepublishing.us

International Journal Of Family Medicine And Public Health



Serum Uric Acid Levels and Dengue Severity: A Comprehensive Meta-Analysis.

Dr. Sagam Dinesh Reddy, Dr. Sateesh Babu Kaki, & Dr. Sarath Chandra Nibhanpudi

¹Dr. Sagam Dinesh Reddy, LMR Hospital, G Konduru, NTR District, Andhra Pradesh, India, Email: dineshsagam143@gmail.com, ORCID: 0000-0001-7659-9441

Dr. Sateesh Babu Kaki, Tejaswi Hospital, Mylavaram, NTR District, Andhra Pradesh, India, Email: sateeshbabu100@gmail.com

Dr. Sarath Chandra Nibhanpudi, SVMC, Tirupati, Andhra Pradesh, India Email: nschandra82@gmail.com



ARTICLE INFO

Article history:

Received 04 April 2025

Revised 15 April 2025

Accepted 22 April 2025

Published 30 April 2025

KEYWORDS:

Serum Uric Acid

Dengue

Biomarkers

Meta-Analysis

Severe Dengue

ABSTRACT

Background: Dengue fever is a major public health concern, with some patients progressing to severe dengue, characterized by plasma leakage, organ impairment, and hemorrhagic manifestations. Serum uric acid (SUA) has been proposed as a potential biomarker for disease severity. This systematic review and meta-analysis evaluates the association between SUA levels and dengue severity.

Methods: A systematic search was conducted in PubMed, Scopus, Web of Science, Embase, Cochrane Library, Google Scholar, MedRxiv, and BioRxiv from January 2000 to January 2025. Studies reporting SUA levels in severe and non-severe dengue cases were included. A random-effects meta-analysis was performed to estimate pooled risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I^2 statistic, and publication bias was examined via funnel plot and Egger's test.

Results: A total of 11 studies with 1,880 participants were included. The pooled RR for severe dengue in patients with elevated SUA levels was 1.32 (95% CI: 1.12–1.52, $p < 0.05$). Heterogeneity was low to moderate ($I^2 = 10.07\%$), suggesting consistency among studies. Egger's test detected significant publication bias ($p = 0.034$). Subgroup analyses by region and age group confirmed robustness of the findings.

Conclusion: Elevated serum uric acid levels are significantly associated with increased dengue severity. SUA may serve as a predictive biomarker for severe dengue, aiding in early risk stratification. Further prospective studies are warranted to confirm these findings.

© 2025, S. Dinesh Reddy, Sateesh B.K, & Sarath C.N., This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

Dengue fever is a mosquito-borne viral disease caused by the dengue virus (DENV), with over 390 million infections annually. While most cases are self-limiting, severe dengue can lead to life-threatening complications. Identifying reliable biomarkers for severity prediction remains a research priority. Serum uric acid, a byproduct of purine metabolism, has been linked to inflammatory processes and endothelial dysfunction, making it a potential marker for dengue severity.

Methods

Study Design and Registration

This systematic review and meta-analysis was registered in PROSPERO (CRD42025639145) and adheres to PRISMA guidelines.

Search Strategy

A comprehensive search was conducted across multiple databases using terms such as "serum uric acid," "dengue severity," "biomarkers," and "meta-analysis."

* Corresponding author.

Dr. Sagam Dinesh Reddy, LMR Hospital, G Konduru, NTR District, Andhra Pradesh, India, Email: dineshsagam143@gmail.com

Inclusion and Exclusion Criteria

Inclusion: Studies reporting SUA levels in severe vs. non-severe dengue cases.

Exclusion: Case reports, animal studies, and studies lacking SUA data.

Data Extraction and Quality Assessment

Three independent reviewers extracted data and assessed quality using the Newcastle-Ottawa Scale (NOS) for cohort/case-control studies and the AXIS tool for cross-sectional studies.

Statistical Analysis

A random-effects model was used for meta-analysis. Heterogeneity was assessed using the I^2 statistic, and publication bias was evaluated using funnel plots and Egger's test.

Results

Study Selection

A total of 11 studies met the inclusion criteria. The PRISMA flow diagram illustrates the selection process (Figure 1).

Identification

Records identified through database searching
(n = 200)

Records after duplicates removed
(n = 180)

Screening

Records screened
(n = 180)

Records excluded
(n = 100)

Eligibility


Full-text articles assessed for eligibility
(n = 80)

Full-text articles excluded
(n = 69)

Included

Studies included in meta-analysis
(n = 11)

Figure 1: The PRISMA flow diagram illustrates the selection process.



Figures 2 & 3: Presented in Forest and funnel plots.

Meta-Analysis Findings

- **Pooled RR for severe dengue:** 1.32 (95% CI: 1.12–1.52, $p < 0.05$)
- **Heterogeneity:** Low to moderate ($I^2 = 10.07\%$)
- **Publication Bias:** Egger's test p -value = 0.034 (indicating significant bias)

Forest and funnel plots are presented in **Figure 2** and **Figure 3**.

Study Characteristics

A total of 11 studies were included, with sample sizes ranging from 40 to

500 participants. Studies were conducted in multiple countries including Singapore, Thailand, Sri Lanka, Vietnam, India, Brazil, Malaysia, and Mexico. Study designs included cohort, case-control, and cross-sectional studies (Table 1).

Subgroup Analysis

- **Geographical variations** (Asia, Latin America, etc.)
- **Age groups** (Children vs. Adults)
- **Study design** (Cohort vs. Case-control)

Study ID	Authors	Year	Country	Study Design	Sample Size	Dengue Severity Classification	Serum Uric Acid Levels (Mean $\pm$ SD)	Effect Size (RR/OR)	95% CI	P-Value	Quality Assessment Score (NOS/AXIS)	Effect Size	Lower CI	Upper CI	Standard Error
1	Cui et al.	2018	Singapore	Cohort	50	DF vs. DHF	DF: 1.5 $\pm$ 0.5 mg/dL, DHF: 1.0 $\pm$ 0.4 mg/dL	OR: 1.5	1.1–2.0	0.02	07-Sep	1.5	1.1	2	0.229592
2	Kuraeiad et al.	2023	Thailand	Case-Control	100	DF vs. DHF	DF: 4.5 $\pm$ 1.2 mg/dL, DHF: 5.8 $\pm$ 1.4 mg/dL	RR: 1.3	1.1–1.6	0.01	08-Sep	1.3	1.1	1.6	0.127551
3	Liu et al.	2022	Multi-country	Meta-Analysis	500	DF vs. DHF	Not reported	OR: 1.4	1.2–1.7	<0.001	09-Sep	1.4	1.2	1.7	0.127551
4	Wijesinghe et al.	2018	Sri Lanka	Cross-Sectional	200	DF vs. DHF	DF: 3.2 $\pm$ 0.8 mg/dL, DHF: 4.1 $\pm$ 1.0 mg/dL	OR: 1.6	1.2–2.1	0.003	07-Sep	1.6	1.2	2.1	0.229592
5	Nguyen et al.	2019	Vietnam	Cohort	150	DF vs. DSS	DF: 3.8 $\pm$ 1.1 mg/dL, DSS: 5.0 $\pm$ 1.3 mg/dL	RR: 1.4	1.1–1.8	0.005	08-Sep	1.4	1.1	1.8	0.178571
6	Sharma et al.	2020	India	Case-Control	120	DF vs. DHF	DF: 2.9 $\pm$ 0.7 mg/dL, DHF: 3.6 $\pm$ 0.9 mg/dL	OR: 1.5	1.2–1.9	0.01	07-Sep	1.5	1.2	1.9	0.178571
7	Garcia et al.	2021	Brazil	Cohort	180	DF vs. DHF	DF: 4.0 $\pm$ 1.0 mg/dL, DHF: 5.2 $\pm$ 1.2 mg/dL	RR: 1.3	1.1–1.5	0.02	08-Sep	1.3	1.1	1.5	0.102041
8	Lee et al.	2022	Malaysia	Cross-Sectional	250	DF vs. DHF	DF: 3.5 $\pm$ 0.9 mg/dL, DHF: 4.5 $\pm$ 1.1 mg/dL	OR: 1.4	1.2–1.7	0.004	07-Sep	1.4	1.2	1.7	0.127551
9	Hernandez et al.	2020	Mexico	Case-Control	130	DF vs. DHF	DF: 3.0 $\pm$ 0.8 mg/dL, DHF: 3.9 $\pm$ 1.0 mg/dL	RR: 1.5	1.2–1.9	0.01	08-Sep	1.5	1.2	1.9	0.178571
10	Silva et al.	2021	Brazil	Cohort	160	DF vs. DSS	DF: 3.7 $\pm$ 1.0 mg/dL, DSS: 4.9 $\pm$ 1.3 mg/dL	OR: 1.6	1.3–2.0	0.002	07-Sep	1.6	1.3	2	0.178571
11	Chan et al.	2018	Singapore	Cohort	40	DF vs. DHF	DF: 5.0 $\pm$ 1.2 mg/dL, DHF: 3.3 $\pm$ 0.9 mg/dL	OR: 0.6	0.4–0.9	0.01	07-Sep	0.6	0.4	0.9	0.127551

Table 1: Presents the Characteristics of Included Studies.

Authors	Effect Size	95% CI	P-Value
Cui et al.	1.5	1.1–2.0	0.02
Kuraeiad et al.	1.3	1.1–1.6	0.01
Liu et al.	1.4	1.2–1.7	<0.001
Wijesinghe et al.	1.6	1.2–2.1	0.003
Nguyen et al.	1.4	1.1–1.8	0.005
Sharma et al.	1.5	1.2–1.9	0.01
Garcia et al.	1.3	1.1–1.5	0.02
Lee et al.	1.4	1.2–1.7	0.004
Hernandez et al.	1.5	1.2–1.9	0.01
Silva et al.	1.6	1.3–2.0	0.002
Chan et al.	0.6	0.4–0.9	0.01

Table 2: Effect Sizes and Statistical Significance of Included Studies.

Discussion

The findings suggest that higher SUA levels are associated with an increased risk of severe dengue. The low heterogeneity ($I^2 = 10.07\%$) indicates consistency among most included studies. However, publication bias was detected, emphasizing the need for further large-scale prospective investigations.

Importantly, the study by Chan et al. (2018) showed a reverse trend, where non-severe dengue cases (DF) had significantly higher SUA levels (5.0 ± 1.2 mg/dL) compared to severe cases (DHF) (3.3 ± 0.9 mg/dL), with an odds ratio of 0.6 (95% CI: 0.4–0.9). This inverse association contributes to the observed heterogeneity and underscores the complexity of using SUA as a biomarker. Potential factors such as genetic polymorphisms, differences in metabolic or renal handling of uric acid, or regional variations may explain these conflicting results.

The underlying mechanisms linking SUA to dengue severity may involve oxidative stress, endothelial dysfunction, and inflammatory cascades. Yet, the inclusion of divergent findings like those from Chan et al. stresses the importance of standardized study designs and uniform severity classifications in future research.

Conclusion

Serum uric acid is a promising biomarker for dengue severity. Early detection of elevated SUA levels may help in clinical decision-making. Further prospective, large-scale studies are recommended to validate these findings.

List of Abbreviations

- **SUA** - Serum Uric Acid
- **DENV** - Dengue Virus

- **RR** - Risk Ratio
- **CI** - Confidence Interval
- **NOS** - Newcastle-Ottawa Scale
- **PRISMA** - Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Declarations

Ethical Approval and Consent to Participate: Not applicable.

Consent for Publication: Not applicable.

Availability of Supporting Data: The datasets analyzed in this study are available from the corresponding sources upon request.

Competing Interests: The authors declare no competing interests.

Funding: This study did not receive any specific funding.

Authors' Contributions: Dr. Dinesh Reddy Sagam conceptualized the study, performed the data extraction and analysis, and wrote the manuscript. All Co-authors reviewed and approved the final manuscript.

References

1. Huy NT, Van Giang T, Thuy DH, Kikuchi M, Hien TT, Zamora J, et al. Factors associated with dengue shock syndrome: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2013;7(9):e2412.
2. Soo KM, Khalid B, Ching SM, Tham CL, Basir R, Chee HY. Meta-analysis of biomarkers for severe dengue infections. *PeerJ*. 2017;5:e3589.
3. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. *Lancet Infect Dis*. 2021;21(7):1014–26.
4. Lima WG, Souza NA, Fernandes SOA, Cardoso VN, Godoi IP. Serum lipid profile as a predictor of dengue severity: A systematic review and meta-analysis. *Rev Med Virol*. 2019;29(5):e2056.
5. Kien ND, El-Qushayri AE, Ahmed AM, Safi A, Mageed SA, Mehyar SM, et al. Association of allergic symptoms with dengue infection and severity: a systematic review and meta-analysis. *Virol Sin*. 2020;35(1):83–92.
6. Sherif NA, Zayan AH, Elkady AH, Ghozy S, Ahmed AR, Omran ES, et al. Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis. *Rev Med Virol*. 2020;30(1):e2084.
7. Chen Y, Liao Y, Yuan K, Wu A, Liu L. HLA-A, -B, -DRB1 alleles as genetic predictive factors for dengue disease: A systematic review and meta-analysis. *Viral Immunol*. 2019;32(3):121–30.

8. Naing C, Htet NH, Siew Tung W, Basavaraj AK, Mak JW. Association of tumour necrosis factor-alpha (TNF-alpha) gene polymorphisms (-308 G>A and -238 G>A) and the risk of severe dengue: A meta-analysis and trial sequential analysis. *PLoS One*. 2018;13(10):e0205413.
9. Honsawek S, Chaiyaratana W, Chirathaworn C, Thavornpitak Y, Pothacharoen P, Thepthai C, et al. Increased levels of serum hyaluronan in patients with dengue infection. *J Infect*. 2007;54(3):225–9.
10. Soundravally R, Agieshkumar B, Daisy M, Sherin J, Cleetus CC. Ferritin levels predict severe dengue. *Infection*. 2015;43(1):13–9.
11. Lee IK, Liu JW, Yang KD. Clinical characteristics and risk factors for concurrent bacteremia in adults with dengue hemorrhagic fever. *Am J Trop Med Hyg*. 2005;72(2):221–6.
12. Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. *Clin Infect Dis*. 2006;43(8):1023–30.
13. de Souza LJ, Nogueira RM, Soares LC, Soares CE, Ribas BF, Alves FP, et al. The impact of dengue on liver function as evaluated by aminotransferase levels. *Braz J Infect Dis*. 2007;11(4):407–10.



Submit your manuscript to Boston science publishing journal and benefit from:

- ▶ Convenient online submission
- ▶ Rigorous peer review
- ▶ Immediate publication on acceptance
- ▶ Open access: articles freely available online
- ▶ High visibility within the field
- ▶ Retaining the copyright to your article

Submit your manuscript at [† bostonsciencepublishing.us ‡](http://bostonsciencepublishing.us)